Basic Information
| LncRNA/CircRNA Name | MFI2-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | clear cell renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR |
| Sample | osteosarcoma cell lines |
| Expression Pattern | up-regulated |
| Function Description | Overall, MFI2-AS1 status improves patient stratification in localized ccRCC, which supports further integration of lncRNAs in molecular cancer classifications.Kaplan-Meier estimates for disease-free survival (DFS) in the validation set. |
| Pubmed ID | 28819235 |
| Year | 2017 |
| Title | Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. |
External Links
| Links for MFI2-AS1 | GenBank HGNC NONCODE |
| Links for clear cell renal cell carcinoma | OMIM COSMIC |